# HCA Healthcare, Inc.: overview

HCA · NYSE · CIK 860730 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/hca.md) · [Financials](/companies/hca/financials.md) · [Filings](/companies/hca/filings.md) · [Insiders](/companies/hca/insiders.md)

Latest reported revenue: [$19.85bn](/filings/0001193125-26-437871.md) for Q3 FY2026, three months to 2026-09-30, from the 10-Q filed Oct 29, 2026 (XBRL us-gaap:Revenues, accession 0001193125-26-437871).

## Last eight quarters

| Line item | Unit | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $bn | [18.3 d](/filings/0001193125-26-044769.md) | [18.3](/filings/0001193125-26-191444.md) | [18.6](/filings/0001193125-26-321077.md) | [19.2](/filings/0001193125-26-437871.md) | [19.5 d](/filings/0001193125-26-044769.md) | [19.1](/filings/0001193125-26-191444.md) | [20.2](/filings/0001193125-26-321077.md) | [19.8](/filings/0001193125-26-437871.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | [7.9% d](/filings/0001193125-26-044769.md) | [8.8%](/filings/0001193125-26-191444.md) | [8.9%](/filings/0001193125-26-321077.md) | [8.6%](/filings/0001193125-26-437871.md) | [9.6% d](/filings/0001193125-26-044769.md) | [8.5%](/filings/0001193125-26-191444.md) | [8.4%](/filings/0001193125-26-321077.md) | [8.0%](/filings/0001193125-26-437871.md) |
| Diluted EPS | $ per share | not reported | [6.45](/filings/0001193125-26-191444.md) | [6.83](/filings/0001193125-26-321077.md) | [6.96](/filings/0001193125-26-437871.md) | not reported | [7.15](/filings/0001193125-26-191444.md) | [7.62](/filings/0001193125-26-321077.md) | [7.27](/filings/0001193125-26-437871.md) |
| Free cash flow | $bn | [1.3 d](/filings/0001193125-26-044769.md) | [0.7](/filings/0001193125-26-191444.md) | [3.0 d](/filings/0001193125-26-321077.md) | [3.1 d](/filings/0001193125-26-437871.md) | [0.9 d](/filings/0001193125-26-044769.md) | [0.9](/filings/0001193125-26-191444.md) | [1.1 d](/filings/0001193125-26-321077.md) | [3.1 d](/filings/0001193125-26-437871.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $bn | [58.8](/filings/0000950170-24-016524.md) | [60.2](/filings/0000950170-25-020134.md) | [65.0](/filings/0001193125-26-044769.md) | [70.6](/filings/0001193125-26-044769.md) | [75.6](/filings/0001193125-26-044769.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | [11.8%](/filings/0000950170-24-016524.md) | [9.4%](/filings/0000950170-25-020134.md) | [8.1%](/filings/0001193125-26-044769.md) | [8.2%](/filings/0001193125-26-044769.md) | [9.0%](/filings/0001193125-26-044769.md) |
| Diluted EPS | $ per share | [21.16](/filings/0000950170-24-016524.md) | [19.15](/filings/0000950170-25-020134.md) | [18.97](/filings/0001193125-26-044769.md) | [22.00](/filings/0001193125-26-044769.md) | [28.33](/filings/0001193125-26-044769.md) |
| Free cash flow | $bn | [5.4](/filings/0000950170-24-016524.md) | [4.1](/filings/0000950170-25-020134.md) | [4.7](/filings/0001193125-26-044769.md) | [5.6](/filings/0001193125-26-044769.md) | [7.7](/filings/0001193125-26-044769.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues.
- Operating margin (operating income / revenue). XBRL Revenue: us-gaap:Revenues.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/hca/insiders.md)

| Date | Insider | Role | Transaction | Shares | Reported price | Value | Filing |
| --- | --- | --- | --- | ---: | ---: | ---: | --- |
| 2016-05-10 | [Kravis Henry R](/insiders/1081714.md) | 10% owner | Sale (S) | 332,799 | $80.12 | $26.7m | [Form 4](/filings/0000899243-16-019814.md) |
| 2016-05-10 | [Kravis Henry R](/insiders/1081714.md) | 10% owner | Sale (S) | 381,309 | $80.12 | $30.6m | [Form 4](/filings/0000899243-16-019814.md) |
| 2016-05-10 | [Kravis Henry R](/insiders/1081714.md) | 10% owner | Sale (S) | 78,529 | $80.12 | $6.3m | [Form 4](/filings/0000899243-16-019814.md) |
| 2016-05-10 | [Kravis Henry R](/insiders/1081714.md) | 10% owner | Sale (S) | 127,923 | $80.12 | $10.2m | [Form 4](/filings/0000899243-16-019814.md) |
| 2016-05-10 | [Kravis Henry R](/insiders/1081714.md) | 10% owner | Sale (S) | 1,249,115 | $80.12 | $100.1m | [Form 4](/filings/0000899243-16-019814.md) |
| 2016-05-10 | [Kravis Henry R](/insiders/1081714.md) | 10% owner | Sale (S) | 3,461,161 | $80.12 | $277.3m | [Form 4](/filings/0000899243-16-019814.md) |
| 2016-05-10 | [Kravis Henry R](/insiders/1081714.md) | 10% owner | Sale (S) | 3,730,122 | $80.12 | $298.9m | [Form 4](/filings/0000899243-16-019814.md) |
| 2012-04-03 | [Bank of America Corp](/insiders/70858.md) | 10% owner | Sale (S) | 300 | $26.83 | $8.0k | [Form 4](/filings/0001140361-25-010977.md) |
| 2012-04-03 | [Bank of America Corp](/insiders/70858.md) | 10% owner | Sale (S) | 112 | $26.83 | $3.0k | [Form 4](/filings/0001140361-25-010977.md) |
| 2012-03-19 | [Bank of America Corp](/insiders/70858.md) | 10% owner | Purchase (P) | 25 | $25.18 | $629.50 | [Form 4](/filings/0001140361-25-010977.md) |
| 2012-03-16 | [Bank of America Corp](/insiders/70858.md) | 10% owner | Sale (S) | 25 | $25.33 | $633.25 | [Form 4](/filings/0001140361-25-010977.md) |
| 2012-03-15 | [Bank of America Corp](/insiders/70858.md) | 10% owner | Sale (S) | 2 | $25.34 | $50.68 | [Form 4](/filings/0001140361-25-010977.md) |
| 2012-03-09 | [Bank of America Corp](/insiders/70858.md) | 10% owner | Purchase (P) | 2 | $25.63 | $51.26 | [Form 4](/filings/0001140361-25-010977.md) |
| 2012-03-08 | [Bank of America Corp](/insiders/70858.md) | 10% owner | Sale (S) | 100 | $25.315 | $2.5k | [Form 4](/filings/0001140361-25-010977.md) |
| 2012-03-08 | [Bank of America Corp](/insiders/70858.md) | 10% owner | Sale (S) | 100 | $25.315 | $2.5k | [Form 4](/filings/0001140361-25-010977.md) |
| 2012-03-08 | [Bank of America Corp](/insiders/70858.md) | 10% owner | Sale (S) | 1,300 | $25.3147 | $32.9k | [Form 4](/filings/0001140361-25-010977.md) |
| 2012-03-08 | [Bank of America Corp](/insiders/70858.md) | 10% owner | Sale (S) | 80 | $25.31 | $2.0k | [Form 4](/filings/0001140361-25-010977.md) |
| 2012-03-08 | [Bank of America Corp](/insiders/70858.md) | 10% owner | Purchase (P) | 1,580 | $25.28 | $39.9k | [Form 4](/filings/0001140361-25-010977.md) |
| 2012-02-22 | [Bank of America Corp](/insiders/70858.md) | 10% owner | Purchase (P) | 200 | $25.4637 | $5.1k | [Form 4](/filings/0001140361-25-010977.md) |
| 2012-02-22 | [Bank of America Corp](/insiders/70858.md) | 10% owner | Sale (S) | 200 | $25.4089 | $5.1k | [Form 4](/filings/0001140361-25-010977.md) |

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $5.07bn | 13,003,600 |  | Reduced −359,666 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $3.95bn | 10,141,708 |  | Reduced −36,654 |
| [Sanders Capital, LLC](/funds/1508097.md) | 2026-06-30 | $3.44bn | 8,828,287 |  | Reduced −128,858 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $2.91bn | 7,469,035 |  | Reduced −70,515 |
| [WELLINGTON MANAGEMENT GROUP LLP](/funds/902219.md) | 2026-06-30 | $1.84bn | 4,707,473 |  | Added +799,761 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $1.42bn | 3,668,008 |  | Reduced −24,505 |
| [First Eagle Investment Management, LLC](/funds/1325447.md) | 2026-06-30 | $1.28bn | 3,295,565 |  | Added +40,995 |
| [First Eagle Investment Management, LLC](/funds/1325447.md) | 2026-06-30 | $1.28bn | 3,295,565 |  | Added +40,995 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $1.06bn | 2,712,828 |  | Reduced −44,951 |
| [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $1.01bn | 2,586,771 |  | Added +291,891 |

## Recent filings

[All 2,306 filings](/companies/hca/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-29 | 16:30 ET | [10-Q](/filings/0001193125-26-437871.md) | Quarterly report, period 2026-09-30 | 0001193125-26-437871 |
| 2026-10-27 | 07:17 ET | [8-K](/filings/0001193125-26-432665.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-432665 |
| 2026-07-29 | 16:10 ET | [8-K](/filings/0001193125-26-323731.md) | 2.03 New direct financial obligation; 8.01 Other events | 0001193125-26-323731 |
| 2026-07-28 | 16:30 ET | [10-Q](/filings/0001193125-26-321077.md) | Quarterly report, period 2026-06-30 | 0001193125-26-321077 |
| 2026-07-24 | 07:45 ET | [8-K](/filings/0001193125-26-315151.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-315151 |
| 2026-07-14 | 07:40 ET | [8-K](/filings/0001193125-26-302539.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-302539 |
| 2026-06-18 | 09:12 ET | [8-K](/filings/0001193125-26-275086.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-275086 |
| 2026-04-30 | 16:10 ET | [8-K](/filings/0001193125-26-197278.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-197278 |
| 2026-04-29 | 16:02 ET | [10-Q](/filings/0001193125-26-191444.md) | Quarterly report, period 2026-03-31 | 0001193125-26-191444 |
| 2026-04-28 | 16:20 ET | [8-K](/filings/0001193125-26-187155.md) | 5.07 Shareholder vote results | 0001193125-26-187155 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-044769.md), filed Feb 10, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 860730
- Tickers: HCA
- Exchange: NYSE
- SIC code: 8062 Services-General Medical & Surgical Hospitals, NEC
- State of incorporation: not reported
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 18:36 ET. No prices; not investment advice.